Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138671 · ClinicalTrials.gov registry record · Phase 3
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT00138671 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 105 participants.
The verdict
NCT00138671, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
Interventions
- DRUG Subcutaneous Insulin
- DRUG Inhaled Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2003-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138671
The ClinicalTrials.gov registry entry for NCT00138671 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Subcutaneous Insulin is the first listed.
NCT00138671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138671 about?
NCT00138671 is a clinical study titled "A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD". A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
What is the current status of trial NCT00138671?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2003-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00138671?
The interventions under investigation include: Subcutaneous Insulin (DRUG), Inhaled Insulin (DRUG).
Who is sponsoring clinical trial NCT00138671?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.